Accueil   Diary - News   All news Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Valneva Announces Signing of a New EB66® Commercial License with Bavarian Nordic

Lyon (France), April 18, 2017 – Valneva SE (“Valneva” or “the Company”), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, today announced that it has entered into a commercial agreement with Danish biotech company Bavarian Nordic (OMX: BAVA, OTC:BVNRY), for the production of poxvirus-based vaccines using Valneva´s EB66® cell-line technology.

 

 

The agreement grants Bavarian Nordic the rights to develop and commercialize multiple poxvirus-based vaccines on the EB66® cell-line.

 

Read the press release

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree